
Sign up to save your podcasts
Or


As recently as a few years ago, the idea of a self-administered injection that would deliver proven weight-loss results might have sounded fantastical. Today, these medications are a reality and a global phenomenon; hailed in many quarters as “miracle drugs" for their success in treating obesity and diabetes. They do this by replicating a gut hormone called GLP‑1, which tells the brain you’ve eaten enough and nudges the pancreas to release insulin; and this hormone was discovered and decoded thanks to years of work by today's guest. Jens Juul Holst is a Professor of Medical Physiology and Biomedical Sciences at the University of Copenhagen. His efforts laid the groundwork for today’s weight loss jabs, earning him a slew of high-profile accolades and awards. Now it seems they might not only have positive impacts on obesity and diabetes, but also other health issues... But alongside the big success comes some big questions: including concerns over side effects, weight regain post-treatment, the black market in such drugs, and their cost and accessibility. In a frank conversation with Professor Jim Al-Khalili, Jens address these issues and shares his hopes for the future of GLP-1-focused research.
By BBC World Service4.4
940940 ratings
As recently as a few years ago, the idea of a self-administered injection that would deliver proven weight-loss results might have sounded fantastical. Today, these medications are a reality and a global phenomenon; hailed in many quarters as “miracle drugs" for their success in treating obesity and diabetes. They do this by replicating a gut hormone called GLP‑1, which tells the brain you’ve eaten enough and nudges the pancreas to release insulin; and this hormone was discovered and decoded thanks to years of work by today's guest. Jens Juul Holst is a Professor of Medical Physiology and Biomedical Sciences at the University of Copenhagen. His efforts laid the groundwork for today’s weight loss jabs, earning him a slew of high-profile accolades and awards. Now it seems they might not only have positive impacts on obesity and diabetes, but also other health issues... But alongside the big success comes some big questions: including concerns over side effects, weight regain post-treatment, the black market in such drugs, and their cost and accessibility. In a frank conversation with Professor Jim Al-Khalili, Jens address these issues and shares his hopes for the future of GLP-1-focused research.

7,913 Listeners

863 Listeners

1,067 Listeners

5,576 Listeners

1,808 Listeners

1,729 Listeners

1,018 Listeners

1,996 Listeners

599 Listeners

756 Listeners

93 Listeners

410 Listeners

429 Listeners

818 Listeners

756 Listeners

746 Listeners

227 Listeners

363 Listeners

471 Listeners

240 Listeners

3,245 Listeners

779 Listeners

116 Listeners

1,010 Listeners